HDAC7
History
| Entity | Tier | Description |
|---|---|---|
 |
2 | relevance in DLBCL not firmly established |
Mutation incidence in large patient cohorts (GAMBL reanalysis)
| Entity | source | frequency (%) |
|---|---|---|
| DLBCL | GAMBL genomes | 2.29 |
| DLBCL | Schmitz cohort | 4.68 |
| DLBCL | Reddy cohort | 2.10 |
| DLBCL | Chapuy cohort | 2.56 |
Mutation pattern and selective pressure estimates
| Entity | aSHM | Significant selection | dN/dS (missense) | dN/dS (nonsense) |
|---|---|---|---|---|
| BL | No | No | 2.610 | 0 |
| DLBCL | No | No | 1.696 | 0 |
| FL | No | No | 6.314 | 0 |
[!NOTE] First described in DLBCL in 2013 by Morin RD
View coding variants in ProteinPaint hg19 or hg38
View all variants in GenomePaint hg19 or hg38
## HDAC7
Expression 
## References 1.
Morin RD, Mungall K, Pleasance E, Mungall AJ, Goya R, Huff RD, Scott DW,
Ding J, Roth A, Chiu R, Corbett RD, Chan FC, Mendez-Lago M, Trinh DL,
Bolger-Munro M, Taylor G, Hadj Khodabakhshi A, Ben-Neriah S, Pon J,
Meissner B, Woolcock B, Farnoud N, Rogic S, Lim EL, Johnson NA, Shah S,
Jones S, Steidl C, Holt R, Birol I, Moore R, Connors JM, Gascoyne RD,
Marra MA. Mutational and structural analysis of diffuse large B-cell
lymphoma using whole-genome sequencing. Blood. 2013 Aug
15;122(7):1256–1265. PMCID: PMC3744992
Citing
If you use the information or data from this site, please cite
Krysta Coyle, Kostiantyn Dreval, Daniel Hodson and Ryan D. Morin. Audit of B-cell cancer genes. Blood Adv (2025) 9 (8): 2019–2031.
Disclaimer
The content in these pages has been populated, in part, by an automated process. Although we have scrutinized every page to ensure accuracy, errors will inevitably exist. If you find an error please report it as an issue and we will address it.
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms.
